Overview Financials News + Filings Key Docs Ownership Insiders
All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Inv. presentation
Quarterly results
|
|
biote Corp.
|
Create: Alert |
All | News | Filings
| Date Filed | Type | Description |
| 08/10/2023 |
8-K
| Quarterly results |
| 05/09/2023 |
8-K
| Quarterly results|
Docs:
|
"UNITED STATES SECURITIES AND EXCHANGE COMMISSION",
"Biote Reports First Quarter 2023 Financial Results New Initiative Targets Long-term Growth Opportunity in Men's Health Company Launches Warrant Exchange Offer and Consent Solicitation Maintains 2023 Financial Guidance",
"Biote Announces Commencement of Exchange Offer and Consent Solicitation Relating to Warrants IRVING, TX - May 9, 2023 - Biote , a leading solutions provider in preventive health care through the delivery of personalized hormone therapy, today announced that it has commenced an exchange offer and consent solicitation relating to its 8,397,624 outstanding public warrants to purchase Class A common stock of the Company $0.0001 par value per share , which warrants trade on the Nasdaq Stock Market under the symbol “BTMDW” and 5,106,508 private placement warrants . The purpose of the Offer and Consent Solicitation is to simplify the Company's capital structure and reduce the potential dilutive impact of the warrants. Until the Expiration Date , we are offering to the holders of Warrants the oppo..." |
|
| 11/08/2022 |
8-K
| Quarterly results |
| 08/15/2022 |
8-K/A
| Quarterly results |
| 08/09/2022 |
8-K
| Quarterly results |
|
|